Advertisement

Clinical Use of Myeloid Growth Factors

  • Andrew Weaver
  • Nydia G. Testa
Part of the Blood Cell Biochemistry book series (BLBI, volume 7)

Abstract

With the development of DNA technology, hematopoietic growth factors have been produced in sufficient quantities to enable them to enter the clinic, and there has been an explosion of clinical trials over the last 5 years attempting to define their role. Some of the more commonly used ones are listed in Table I. There are an ever-increasing number of conditions in which hematopoietic growth factors are used, and for any one condition an increasing number of growth factors or combination of factors are being tested in the form of clinical trials. Many would argue that our access to these powerful molecules has, in many ways, outstripped our knowledge of how to use them effectively.

Keywords

Acute Myeloid Leukemia Myelodysplastic Syndrome Dose Intensity Peripheral Blood Stem Cell Allogeneic Bone Marrow Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Advani, R., Greenberg, P., and Gulati, S., 1990, Randomized placebo controlled trial of granulocyte—macrophage colony-stimulating factor in patients undergoing autologous bone marrow transplantation, Blood 76 (Suppl. 1): 525.Google Scholar
  2. Advani, R., Chao, N. J., Horning, S. J., 1992, Granulocyte—macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem-cell transplantation for lymphoma, Ann. Intern. Med. 116: 183–189.PubMedGoogle Scholar
  3. Aglietta, M., Piacibello, W., and Sanavio, F., 1989, Kinetics of human hemopoietic cells after in vivo administration of granulocyte—macrophage colony-stimulating factor, J. Clin. Invest. 83: 551–557.PubMedGoogle Scholar
  4. Ahmed, T., Preti, R. A., Lake, D. E., Farley, T., Cook, P., Hohwart, C., Razis, E., Beer, M., Syed, N., and Ciavarella, D., 1994, Comparison of 2 different doses of sargramostim to mobilize peripheral blood progenitors, Blood 84 (Suppl. 1): 414.Google Scholar
  5. Antin, J. H., Weinberg, D. S., and Rosenthal, D. S., 1990, Variable effect of recombinant human granulocyte—macrophage colony-stimulating factor on bone marrow fibrosis in patients with myelodysplasia, Exp. Hematol. 18: 266–270.PubMedGoogle Scholar
  6. Antman, K., Griffin, J., Elias, A., Socinski, M. A., Ryan, L., Cannistra, S. A., Oette, D., Whitley, M., Frei, E. III, and Schnipper, L. E.,1988, Effect of recombinant human granulocyte—macrophage colony-stimulating factor on chemotherapy-induced myelosuppression, N. Engl. J. Med. 319: 593–598.Google Scholar
  7. Aso, Y., and Akaza, H., 1992, Effect of recombinant human granulocyte colony-stimulating factor in patients receiving chemotherapy for urogenital cancer, J. Urol. 147: 1060–1064.PubMedGoogle Scholar
  8. Barr, R. D., Whang-Penn, J., and Perry, S., 1975, Hematopoietic stem cells in human peripheral blood, Science 190: 284–285.PubMedGoogle Scholar
  9. Behrens, B. C., Grotzingen, K. R., and Hamilton, T. C., 1985, Cytotoxicity of 3 cisplatin analogues in drug sensitive and a new cisplatin resistant human ovarian cancer cell line, Proc. Am. Assoc. Cancer Res. 26: 262.Google Scholar
  10. Bennett, C. L., Greenberg, P., and Gulati, S. C., 1990, GM-CSF decreases duration of cytopenia and hospitalization, and in-hospital costs in patients with Hodgkin’s disease treated with high-dose chemotherapy and autologous bone marrow transfusion (ABMT), Blood 76 (Suppl. 1): 152.Google Scholar
  11. Bensinger, W., Singer, J., Appelbaum, F., and Lilleby, K., 1993, Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant human granulocyte colony-stimulating factor, Blood 81: 3158–3163.PubMedGoogle Scholar
  12. Bettelheim, R, Valent, P., Andreeff, M., Tafuri, A., Haimi, J., Gorischek, C., Muhm, M., Sillaber, C. H., Haas, O., Vieder, L., Mauer, D., Schulz, G., Speiser, W., Geissler, K., Kier, E, Hinterberger, W., and Lechner, K., 1991, Recombinant human granulocyte—macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia, Blood 77: 700–711.PubMedGoogle Scholar
  13. Bhalla, K., Birkhofer, M., Arlin, Z., Grant, S., Lutzky, J., and Graham, G., 1988, Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells, Leukemia 2: 810–813.PubMedGoogle Scholar
  14. Blazar, B. R., Kershey, J. U., and McGlave, P. B., 1989, In vivo administration of recombinant human granulocyte—macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts, Blood 73: 849–857.Google Scholar
  15. Boente, R, Sampaio, C., Brandao, M., Moreira, E. D., Badaro, R., and Jones, T. C., 1993, Local peri-lesional therapy with rhGM-CSF for Kaposi’s sarcoma, Lancet 341: 1154.PubMedGoogle Scholar
  16. Boiron, J. M., Marit, G., and Faberes, C., 1993, Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte—macrophage colony-stimulating factor (rhGM-CSF), Bone Marrow Transplant 12: 49–55.PubMedGoogle Scholar
  17. Bonnadonna, G., 1987, Hodgkin’s disease: The Milan Cancer Institute experience with MOPP and ABVD, in Third International Conference on Malignant Lymphoma, Conference Proceedings.Google Scholar
  18. Bonnet, D., Lemoine, F., Baillou, C., Najman, A., and Guigon, M., 1992, The tetrapeptide acetyl-N-Ser-Asp-LysPro inhibits the response of human purified marrow CD34+ cells to growth factors, Exp. Hematol. 20: 759.Google Scholar
  19. Brandt, S. J., Peters, W. P., and Atwater, S. K., 1988, Effect of recombinant human granulocyte—macrophage colony-stimulating factor on hematopoietic reconstitution after high dose chemotherapy and autologous bone marrow transplantation, N. Engl. J. Med. 318: 869–876.PubMedGoogle Scholar
  20. Bronchud, M. H., Scarffe, J. H., Thatcher, N., and Crowther, D., 1987, Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer, Br. J. Cancer 56: 809–813.PubMedGoogle Scholar
  21. Bronchud, M. H., Howell, A., and Crowther, D., 1989, The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer, Br. J. Cancer 60: 121–125.PubMedGoogle Scholar
  22. Broxmeyer, H. E., Sherry, B., and Lilu, P., 1989, Myelopoietic enhancing effects of murine macrophage marrow granulocyte/macrophage progenitor cells, J. Exp. Hematol. 170: 1583–1594.Google Scholar
  23. Brugger, W., Bross, K., Glatt, M., Weber, F., Mertelsmann, R., and Kanz, L., 1994, Mobilization of tumor cells and hemopoietic progenitor cells into peripheral blood of patients with solid tumours, Blood 83 (3): 636–640.PubMedGoogle Scholar
  24. Buchner, T., Hiddemann, W., Koenigsmann, M., Zuhlsdorf, M., Wormann, B., Boeckmann, A., Freire, E. A., Innig, C., Maschmeyer, G., Ludwig, W. D., Sauerland, M. C., Heinecke, A., and Schulz, G., 1991, Recombinant human granulocyte—macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse, Blood 78: 1190–1197.PubMedGoogle Scholar
  25. Cannistra, S. A., Groshek, P., and Griffin, J. D., 1989, Granulocyte—macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia, Leukemia 3: 328–334.PubMedGoogle Scholar
  26. Cannistra, S. A., DiCarlo, J., Groshek, P., Kanakura, Y., Berg, D., Mayer, R. J., and Griffin, J. D., 1991, Simultaneous administration of granulocyte—macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia, Leukemia 5: 230–238.PubMedGoogle Scholar
  27. Carde, P., Chastang, C., Goncalves, E., Mathieu-Tubiana, N., Vuillemin, E., Delwail, V., and Corbion, 0., 1992, Seraspenide (AcSDKP): Etude en phase I-II d’un inhibiteur de l’hematopoiese protegeant de la toxicite de monochimiotherapies aracytine et ifosfamide, C.R. Acad. Sci. (Paris) 315 (Serie III): 545–550.Google Scholar
  28. Cebon, J., and Lieschke, G. J., 1994, Granulocyte—macrophage colony-stimulating factor for cancer treatment, Oncology 51: 177–188.PubMedGoogle Scholar
  29. Cebon, J., Layton, J., Pavlovic, R., laria, J., Dyer, W., and Morstyn, G., 1991, Endogenous cytokine production in response to sepsis in neutropaenic and non-neutropaenic patients, Blood 78 (Suppl.): 8 (Abstract 23).Google Scholar
  30. Chevallier, B., Bui, N. B., and Bonichon, F., 1992, Efficacy of rG-CSF on haematologic tolerance to MAID chemotherapy in sarcoma patients and impact on dose intensity, Proc. Am. Soc. Clin. Oncol. 11: 1446.Google Scholar
  31. Chevallier, B., Challet, P. H., and Merrouche, Y., 1993, Glycosylated rHuG-CSF (lenograstim) prevents morbidity from FEC HD chemotherapy in inflammatory breast cancer, Proc. Am. Soc. Clin. Oncol. 12: 137.Google Scholar
  32. Clarkson, B., Strife, A., Fried, J., Sakai, Y., Ota, K., Ohkita, T., and Masuda, R., 1970, Studies of cellular proliferation in human leukemia IV. Behaviour of leukemia cells in 3 adults with acute leukemia given continuous infusions of 3H-thymidine for 8–10 days, Cancer 26: 1–19.PubMedGoogle Scholar
  33. Coltman, C. A., Jr., Jones, S. E., and Grozea, P. N., 1978, Bleomycin in combination with MOPP for the management of Hodgkin’s disease: Southwest Oncology Group experience, in Bleomycin: Current Status and New Developments (S. K. Carter and S. T. Crooke, eds.), pp. 227–242, Academic Press, Orlando.Google Scholar
  34. Coltman, C. A., Dahlberg, S., and Jones, S. E., 1986, CHOP is curative in thirty percent of patients with large-cell lymphoma: A twelve year Southwest Oncology Group follow-up, in Advances in Cancer Chemotherapy: Update on Treatment forDiffuse Large-Cell Lymphoma ( A. T. Skarin, ed.), pp. 71–82, John Wiley, New York.Google Scholar
  35. Crawford, J., Ozer, H., and Stoller, R., 1991, Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer, N. Engl. J. Med. 325: 164–170.PubMedGoogle Scholar
  36. Demuynck, H., Pettengell, R., Testa, N. G., and Dexter, T. M., 1992, The engraftment capacity of peripheral blood progenitor cells (PBPC) mobilized with chemotherapy +1— G-CSF, Int. J. Cell Cloning 10 (Suppl. 1): 59–61.Google Scholar
  37. de Revel, T., Appelbaum, F. R., Storb, R., Scheuning, F., Nash, R., Deeg, J., McNiece, I., Andrews, R., and Graham, T., 1994, Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilisation of peripheral blood cells that engraft lethally irradiated dogs, Blood 83: 3795–3799.PubMedGoogle Scholar
  38. Devereux, S., Linch, D. C., and Gribben, J. G., 1989, GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin’s disease, Bone Marrow Transplant 4: 49–54.Google Scholar
  39. DeVita, V. T., 1989, Principles of chemotherapy, in Cancer Principles and Practice of Oncology ( V. T. DeVita, S. Hellman, and S. A. Rosenberg, eds.), pp. 276–300, J. B. Lippincott, Philadelphia.Google Scholar
  40. DeVita, V. T., Simon, R. M., and Hubbard, S. M., 1980, Curability of advanced Hodgkin’s disease with chemotherapy. Long term follow-up of MOPP treated patients at the NCI, Ann. Intern. Med. 92: 587–595.PubMedGoogle Scholar
  41. DeVita, V. T., Jr., Hubbard, S. M., and Longo, D. L., 1987, The chemotherapy of lymphomas: Looking back, moving forward, Cancer Res. 47: 5810.Google Scholar
  42. de Vries, E.G. E., Biesma, B., Willemse, P. H. B., Mulder, N. H., Stern, A. C., Aalders, J. G., and Vellenga, E., 1991, A double blind placebo controlled study with granulocyte—macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma, Cancer Res. 51: 116–122.PubMedGoogle Scholar
  43. De Witte, T., Gratwohl, A., Van Der Lely, N., Bacigalupo, A., Stern, A. C., Speck, B., Schattenberg, A., Nissen, C., Gluckman, E., and Fibbe, W. E., 1992, Recombinant human granulocyte—macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell depleted bone marrow transplantation, Blood 79: 1359–1365.PubMedGoogle Scholar
  44. D’Hondt, V., Weynants, P., and Humblet, Y., 1993, Dose dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small cell lung carcinoma before and following chemotherapy: A placebo controlled randomised phase lb study, J. Clin. Oncol. 11: 2063–2071.PubMedGoogle Scholar
  45. Dreger, P., Haferlach, T., and Eckstein, V., 1994, G-CSF mobilized peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilization and composition of the graft, Br. J. Haematol. 87: 609–613.PubMedGoogle Scholar
  46. Edmonson, J. H., Long, H. J., and Jeffries, J. A., 1989, Amelioration of chemotherapy-induced thrombocytopaenia by GM-CSF: Apparent dose and schedule dependency, J. Natl. Cancer Inst. 81: 1510–1512.PubMedGoogle Scholar
  47. Edmonson, J. H., Colon-Otero, G., Long, H. J., Fitch, T. R., Jeffries, J. A., Buckner, J. C., Rubin, J., and Braich, T. A., 1990, Granulocyte—macrophage colony-stimulating factor (GM-CSF) permits escalation of carboplatin (CBDCA) doses, Proc. Am. Soc. Clin. Oncol. 9: 85.Google Scholar
  48. Engelhard, M., Gerhartz, H., and Brittinger, G., 1993, Cytokine efficiency in the treatment of high grade malignant non-Hodgkin’s lymphomas: Results of a randomised double-blind placebo-controlled study with intensified COP-BLAM +1— rhGM-CSF, in Proceedings of the 5th International Conference on Malignant Lymphoma, Lugano, p. 29.Google Scholar
  49. Estey, E., Thall, P. F., Kantarjian, H., O’Brien, S., Koller, C. A., Beran, M., Gutterman, J., Deisseroth, A., and Keating, M., 1992, Treatment of newly diagnosed acute myelogenous leukemia with granulocyte—macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF, Blood 79: 2246–2255.PubMedGoogle Scholar
  50. Eto, T., Takamatsu, Y., Harada, M., Harada, N., Akashi, K., Teshima, T., Inaba, S., Okamura, T., and Niho, Y., 1994, Effects of macrophage colony-stimulating factor (M-CSF) on the mobilization of peripheral blood stem cells, Bone Marrow Transplant. 13 (2): 125–129.PubMedGoogle Scholar
  51. Fibbe, W. E., Raemaekers, J., Verdonck, L. E, Schouten, H. C., van Imhof, G., and Tromp, B., 1991, Recombinant human interleukin-3 after autologous bone marrow transplantation for malignant lymphoma: Aphase UII multicentre study, Blood 78: 163.Google Scholar
  52. Frei, E. III, and Canellos, G. P., 1980, Dose: A critical factor in cancer chemotherapy, Am. J. Med. 69:585–594. Frindel, E., and Guigon, M., 1977, Inhibition of CFU entry into cycle by a bone marrow extract, Exp. Hematol. 5: 74–76.Google Scholar
  53. Fukuoka, M., Takada, M., and Masuda, N., 1992, Dose intensive weekly chemotherapy with or without recombinant human granulocyte colony-stimulating factor (G-CSF) in extensive stage small cell lung cancer, Proc. Am. Soc. Clin. Oncol. 11: 967.Google Scholar
  54. Gabrilove, J. L., Jakubowski, A., and Scher, H., 1988, Effect of granulocyte colony-stimulating factor on neutropaenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium, N. Engl. J. Med. 318: 1414–1422.PubMedGoogle Scholar
  55. Ganser, A., Volkers, B., Greher, J., Ottmann, O. G., Walther, F., Becher, R., Bergmann, L., Schulz, G., and Hoelzer, D., 1989b, Recombinant human granulocyte–macrophage colony-stimulating factor in patients with myelodysplastic syndromes—a phase I/II trial, Blood 73: 31–37.PubMedGoogle Scholar
  56. Gianni, A. M., Siena, S., and Bregni, M., 1989, Granulocyte–macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation, Lancet 2: 580–585.PubMedGoogle Scholar
  57. Gianni, A., Bregni, M., Siena, S., Orazi, A., Stem, A. C., Gandola, L., and Bonnadonna, G., 1990a, Recombinant granulocyte–macrophage colony-stimulating factor reduces hematological toxicity and widens clinical applicability of high dose cyclophosphamide treatment in breast cancer and non-Hodgkin’s lymphoma, J. Clin. Oncol. 8: 768–778.PubMedGoogle Scholar
  58. Gianni, A. M., Siena, S., and Bregni, M., 19906, Factors influencing the yield of circulating hematopoietic progenitor cells harvested from cancer patients after high-dose cyclophosphamide treatment, with or without RHGM-CSF infusion, in Biology and Clinical Application of Granulocyte–Macrophage Colony-Stimulating Factor (W. E. Fibbe, ed.), pp. 20–28, Sandoz/Schering-Plough, Uden.Google Scholar
  59. Gianni, A. M., Bregni, M., Siena, S., Magni, M., Di Nicola, M., Lombardi, F., Tarella, C., Pileri, A., and Bonnadonna, G., 1992, Granulocyte–macrophage colony-stimulating factor or granulocyte colony-stimulating factor makes high-dose etoposide a safe out-patient regimen that is effective in lymphoma and myeloma patients, J. Clin. Oncol. 10: 1955–1962.PubMedGoogle Scholar
  60. Gianni, A. M., Bregni, M., and Siena, S., 1994, 5-year update of the Milan Cancer Institute randomized trial of high-dose sequential (HDS) vs. MACOP-B therapy for diffuse large-cell lymphomas, Proc. Am. Soc. Clin. Oncol. 13: 1263.Google Scholar
  61. Glaspy, J., McNiece, I., LeMaistre, F., Menchaca, D., Briddell, R., Lill, M., Jones, R., Morstyn, G., and Shpall, E. J., 1994, Effects of stem cell factor and filgrastim on mobilization of peripheral blood progenitor cells and on hematological recovery posttransplant: Early results from a phase I/II study, Proc. Am. Soc. Clin. Oncol. 13: 76.Google Scholar
  62. Goodman, J. W., and Hodgson, G. S., 1962, Evidence for stem cells in the peripheral blood of mice, Blood 19: 702–714.PubMedGoogle Scholar
  63. Gorin, N. C., Coiffier, B., and Pico, J., 1990, Granulocyte–macrophage colony-stimulating factor (GM-CSF) shortens aplasia duration after autologous bone marrow transplantation (ABMT) in non-Hodgkin’s lymphoma: A randomized placebo controlled double-blind study, Blood 76 (Suppl. 1): 542.Google Scholar
  64. Guigon, M., Bonnet, D., Lemoine, F., Kobari, L., Parmentier, C., Mary, J. Y., and Najman, A., 1990, Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP, Exp. Hematol. 18: 1112–1115.PubMedGoogle Scholar
  65. Hansen, P. B., Johnsen, H. E., Hippe, E., and Ralfkiaer, E., 1992, Recombinant human granulocyte–macrophage colony-stimulating factor plus human erythropoietin may improve anaemia in selected patients with myelodysplasia, Blood 80 (Suppl. 1): 846.Google Scholar
  66. Harrousseau, J. L., 1992, Lenograstim after bone marrow transplantation; results of a European multicenter randomised study in 315 patients, in Satellite Symposium to the 24th Congress, International Society of Haematology, London.Google Scholar
  67. Havemann, K., Klausmann, M., Wolf, M., Fischer, J. R., Drings, P., and Oster, W., 1991, Effect of rhGM-CSF on haemopoietic reconstitution after chemotherapy in small cell lung cancer, J. Cancer Res. Clin. Oncol. 117 (Suppl. 4): S203–207.Google Scholar
  68. Hellman, S., Jaffe, E. S., and DeVita, V. T., Jr., 1989, Hodgkin’s disease, in Cancer Principles and Practice of Oncology ( V. T. DeVita, S. Hellman, and S. A. Rosenberg, eds.), pp. 1696–1740, J. B. Lippincott, Philadelphia.Google Scholar
  69. Hellstrom-Lindberg, E., Birgegard, G., Carlsson, M., Carneskog, J., and Dahl, I. M., 1992, Treatment of myelodysplastic syndromes (MDS) with a combination of G-CSF and erythropoietin—A synergistic effect on the erythropoietic response, Blood 80 (Suppl. 1): 84a.Google Scholar
  70. Herrmann, F., Lindemann, A., Klein, H., Lubbert, M., Schulz, G., and Mertelsmann, R., 1989, Effect of recombinant human granulocyte–macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts, Leukemia 3: 335–338.PubMedGoogle Scholar
  71. Herrmann, F., Schulz, G., Wiesier, M., Kolbe, K., Nicolay, U., Noack, M., Lindemann, A., and Mertelsmann, R., 1990, Effect of granulocyte–macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy, Am. J. Med. 88: 619–624.PubMedGoogle Scholar
  72. Hershko, C., Ho, W. G., and Gale, R. P., 1979, Cure of aplastic anaemia in paroxysmal nocturnal haemoglobinuria by marrow transfusion from identical twin: Failure of peripheral leukocyte transfusion to correct marrow aplasia, Lancet 1: 945–947.PubMedGoogle Scholar
  73. Hoekman, K., Wagstaff, J., van-Groeningen, C. J., Vermorken, J. B., Boven, E., and Pinedo, H. M., 1991, Effects of recombinant human granulocyte–macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer, J. Natl. Cancer Inst. 83: 1546–1553.PubMedGoogle Scholar
  74. Jones, H. M., Jones, S. A., Watts, M. J., Khwaja, A., Mills, W., Fielding, A., Goldstone, A. H., and Linch, D. C., 1994, Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma, J. Clin. Oncol. 12 (8): 1693–1702.PubMedGoogle Scholar
  75. Kaplan, G., and Cohn, Z. A., 1993, Effects of intradermal recombinant human granulocyte–macrophage colony-stimulating factor on Langerhans cell recruitment and keratinocyte growth, in Hemopoietic Growth Factors and Mononuclear Phagocytes ( R. Van Furth, ed.), pp. 205–210, S. Karger, Basel.Google Scholar
  76. Kessinger, A., Armitage, J. O., Landmark, J. D., Smith, D. M., and Weisenburger, D. D., 1988, Autologous peripheral haematopoietic stem cell transplantation restores function following marrow ablative therapy, Blood 71: 723–727.PubMedGoogle Scholar
  77. Kobayashi, Y., Okabe, T., and Ozawa, K., 1989, Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: A preliminary report, Am. J. Med. 86: 178–182.PubMedGoogle Scholar
  78. Korbling, M., Juttner, C., Henon, P., and Kessinger, A., 1992, Autologous blood stem cell versus bone marrow transplantation, Bone Marrow Transplant. 10 (Suppl. 1): 144–148.PubMedGoogle Scholar
  79. Kotake, T., Miki, T., and Akaza, H., 1991, Effect of recombinant granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer, Cancer Chemother. Pharmacol. 27: 253–257.PubMedGoogle Scholar
  80. Kurzrock, R., Talpez, M., Estey, E. H., and Gutterman, J. U., 1991, Haemopoietic growth factors in bone marrow failure states, Cancer Bull. 43: 215–23.Google Scholar
  81. Kushner, B. H., Kwon, J.-H., Gulati, S. C., and Castro-Malaspina, H., 1987, Preclinical assessment of purging with VP-16–213: Key role for long-term marrow cultures, Blood 69: 65–71.PubMedGoogle Scholar
  82. Lazarus, H., Andersen, J., and Oette, D., 1990, Phase II ECOG trial of recombinant human granulocyte–macrophage colony-stimulating factor (rhGM-CSF) after autologous bone marrow transplant (AuBMT) for relapsed non-Hodgkin’s lymphoma (NHL), Proc. Am. Soc. Clin. Oncol. 9: 15.Google Scholar
  83. Lenfant, M., Wdzieczak-Bakala, J., Guittet, E., Prome, J. C., Sotty, D., and Frindel, E., 1989, Inhibitor of hematopoietic pluripotent stem cell proliferation: Purification and determination of its structure, Proc. Natl. Acad. Sci. U.S.A. 36: 779–782.Google Scholar
  84. Levin, L., and Hryniuk, W. M., 1987, Dose intensity analysis of chemotherapy regimens in ovarian carcinoma, J. Clin. Oncol. 5: 756–767.PubMedGoogle Scholar
  85. Lichtman, S., Ratain, M., Budman, D. R., Norton, L., Egorin, M., Propert, K., Modeas, C., Paterson, D., and Van Echo, D. A., 1989, Phase I trial of recombinant granulocyte–macrophage colony-stimulating factor (GMCSF) plus cyclophosphamide in solid tumours, Blood 74: 328.Google Scholar
  86. Linch, D. C., 1992, Lenograstim. A new glycosylated rHuG-CSF; pharmacology and clinical profile in bone marrow transplants. Chugai–Rhone-Poulenc Symposium, Br. J. Haematol. 82: 274–275.Google Scholar
  87. Link, H., 1990, Recombinant human granulocyte–macrophage colony-stimulating factor (rhGM-CSF) for hematological reconstitution after autologous bone marrow transplantation, in: Hematopoietic Growth Factors in Clinical Applications ( R. Mertelsmann and F. Herrmann, eds.), pp. 313–335, Marcel Dekker, New York.Google Scholar
  88. Link, H., Boogaerts, M., and Carella, A., 1990a, Recombinant human granulocyte–macrophage colony-stimulating factor (rhGM-CSF) after autologous bone marrow transplantation for acute lymphoblastic leukemia and non-Hodgkin’s lymphoma: A randomized double-blind multicentre trial in Europe, Blood 76 (Suppl. 1): 152.Google Scholar
  89. Link, H., Diedrich, H., and Ebell, W., 1990b, Recombinant human erythropoietin after allogeneic bone marrow transplantation, Bone Marrow Transplant 5 (Suppl. 2): 219a.Google Scholar
  90. Lord, B. I., Mori, K. J., Wright, E. G., and Lajtha, L. G., 1976, An inhibitor of stem cell proliferation in normal bone marrow, Br. J. Haematol. 34: 441–445.PubMedGoogle Scholar
  91. Lord, B. I., Mori, K. J., and Wright, E. G., 1977, A stimulator of stem cell proliferation in regenerating bone marrow, Biomed. Exp. 27: 223–226.Google Scholar
  92. Masaoka, T., Motoyoshi, K., and Takaku, I., 1988, Administration of human urinary colony-stimulating factor after bone marrow transplantation, Bone Marrow Transplant 3: 121–127.PubMedGoogle Scholar
  93. McCarthy, D. M., and Goldman, J. M., 1984, Transfusion of circulating stem cells, CRC Crit. Rev. Clin. Lab. Sci. 20: 1–24.Google Scholar
  94. McCredie, K., Hersh, E., and Freireich, E., 1971, Cells capable of colony formation in the peripheral blood of man, Science 171: 293–294.PubMedGoogle Scholar
  95. McKenzie, S., New, M., and Hirschfeld, N., 1990, GM-CSF in pediatric bone marrow transplantation: A phase I11I study, Blood 76 (Suppl. 1): 553.Google Scholar
  96. Mertelsmann, R., 1991, Hematopoietins: Biology, pathophysiology, and potential as therapeutic agents, Ann. Oncol. 2 (4): 251–263.PubMedGoogle Scholar
  97. Metcalf, D., 1994, Thrombopoietin—at last, Nature 369: 519.PubMedGoogle Scholar
  98. Michon, J., Bouffet, E., and Bernard, J. L., 1990, Administration of recombinant human GM-CSF after autologous bone marrow transplantation (ABMT). A study of 21 stage IV neuroblastoma patients undergoing a double intensification regimen, Proc. Am. Soc. Clin. Oncol. 9: 184.Google Scholar
  99. Micklem, H. S., Anderson, N., and Ross, R., 1975, Limited potential of circulating hemopoietic stem cells, Nature 256: 41–43.PubMedGoogle Scholar
  100. Molineux, G., Pojda, Z., Hampson, I. N., Lord, B. I., and Dexter, T. M., 1990, Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor, Blood 76 (10): 2153–2158.PubMedGoogle Scholar
  101. Molineux, G., Migdalska, A., Szmitkowski, M., Zsebo, K., and Dexter, T. M., 1991, The effects on hematopoiesis of recombinant stem cell factor (ligand for c-kit) administered in vivo to mice either alone or in combination with granulocyte colony-stimulating factor, Blood 78: 961–966.PubMedGoogle Scholar
  102. Molineux, G., Migdalska, A., Haley, J., Evans, G. S., and Dexter, T. M., 1994, Total marrow failure induced by pegylated stem cell factor administered before 5-Iluorouracil, Blood 83: 3491–3499.PubMedGoogle Scholar
  103. Monpezat, J. P., and Frindel, E., 1989, Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP on GM-CFC and on the possible involvement of T lymphocytes in AcSDKP response, Exp. Hematol. 17: 1077–1080.PubMedGoogle Scholar
  104. Negrin, R. S., Haeuber, D. H., and Nagler, A., 1989, Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I–II trial, Ann. Inter. Med. 110: 976–984.Google Scholar
  105. Negrin, R. S., Haeuber, D. H., and Nagler, A., 1990, Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor, Blood 76: 36–43.PubMedGoogle Scholar
  106. Neidhart, J., Mangalik, A., and Kohler, W., 1989, Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation, J. Clin. Oncol. 7: 1685–1692.PubMedGoogle Scholar
  107. Neidhart, J., Stidley, G., and Ferguson, J., 1990, GM-CSF decreases duration of cytopenia in patients receiving dose intensive therapy with cyclophosphamide, etoposide and cisplatin, Proc. Am. Soc. Clin. Oncol. 9: 753.Google Scholar
  108. Nemunaitis, J., Singer, J. W., and Buckner, C. D., 1988, Use of recombinant human granulocyte–macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies, Blood 72 (2): 834–836.PubMedGoogle Scholar
  109. Nemunaitis, J., Buckner, C. J., Appelbaum, E. R., Higano, C. S., Mor, M., Bianco, J., Epstein, C., Lipani, J., Hansen, J., Storb, R., Thomas, E. D., and Singer, J. W., 1991a, Phase I/II trial of recombinant human granulocyte–macrophage colony-stimulating factor following allogeneic bone marrow transplantation, Blood 77: 2065–2071.PubMedGoogle Scholar
  110. Nemunaitis, J., Rabinowe, S. N., and Singer, J. W., 1991b, Recombinant human granulocyte–macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer, N. Engl. J. Med. 324 (24): 1773–1778.PubMedGoogle Scholar
  111. Nemunaitis, J., Buckner, C. D., Appelbaum, F. R., Lilleby, K., Wolff, S., and Bierman, P., 1992, Phase I trial with recombinant interleukin-3 (IL-3) in patients with lymphoid cancer undergoing autologous bone marrow transplantation (ABMT), Blood 80: 85.Google Scholar
  112. O’Dwyer, P. J., LaCreta, F. P., Schilder, R., Nash, S., McAleer, C., Miller, L. L., Hudes, G. R., and Ozols, R. F., 1992, Phase I trial of thiotepa in combination with recombinant human granulocyte—macrophage colony-stimulating factor, J. Clin. Oncol. 10: 1352–1358.PubMedGoogle Scholar
  113. Ohno, R., Tomonaga, M., and Kobayashi, T., 1990, Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia: A randomized controlled study, N. Engl. J. Med. 323:871–877.Google Scholar
  114. Ossenkoppele, G. J., Jonhoff, A. R., and Huijgens, P. C., 1993, Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma, Bone Marrow Transplant 11: 103–108.Google Scholar
  115. Ottmann, O. G., Ganser, A., Seipelt, G., Eder, M., Schulz, G., and Hoelzer, D., 1990, Effects of human recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo. Blood 76: 1494–1502.Google Scholar
  116. Pene, R., Appelbaum, F. R., Fisher, L., Lilleby, K., Nemunaitis, J., Storb, R., and Buckner, C. D., 1993, Use of granulocyte—macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation, Bone Marrow Transplant 11: 219–222.PubMedGoogle Scholar
  117. Peters, W. P., 1989, The effect of recombinant human colony-stimulating factors hemopoietic reconstitution following autologous bone marrow transplantation, Semin. Hematol. 26 (Suppl. 2): 18–23.PubMedGoogle Scholar
  118. Peters, W. R, Kurtzberg, J., and Atwater, S., 1989, Comparative effects of r-HuG-CSF and r-HuGM-CSF on haemopoietic reconstitution and granulocyte function following high dose chemotherapy and autologous bone marrow transplantation(ABMT), Proc. Am. Soc. Clin. Oncol. 8: 702.Google Scholar
  119. Peters, W. P., Hussein, A. M., Kurtzberg, J., Ross, M., Vredenburgh, J., Gilbert, C., and Coniglio, D., 1991, Use of recombinant human interleukin-3 (IL-3) in patients (PTS) with metastatic breast cancer receiving high dose chemotherapy (HDC) and chemo-immunologically purged autologous bone marrow transplantation, Blood 78: 162.Google Scholar
  120. Pettengell, R., Gurney, H., Radford, J. A., Deakin, D. P., James, R., Wilkinson, P. M., Testa, N. G., and Crowther, D., 1992, Granulocyte colony-stimulating factor to prevent dose limiting neutropenia in non-Hodgkin’s lymphoma; a randomised controlled trial, Blood 80: 1430–1436.PubMedGoogle Scholar
  121. Pettengell, R., Morgenstern, G. R., Woll, P. J., Chang, J., Rowlands, M., Young, R., Radford, J. A., Scarffe, J. H., Testa, N. G., and Crowther, D., 1993, Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis, Blood 82 (12): 3770–3777.PubMedGoogle Scholar
  122. Pettengell, R., Woll, R. J., Thatcher, N., Dexter, T. M., and Testa, N. G., 1995, Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of haemopoietic progenitors in whole blood, J. Clin. Oncol. 13: 148–156.PubMedGoogle Scholar
  123. Piccart, M., van der Schueren, E., and Bruning, P., 1991, High dose-intensity (DI) chemotherapy (CT) with epiadriamycin (E), cyclophosphamide (C) and r-metHuG-CSF (AMGEN) in breast cancer (BC) patients, Eur. J. Cancer 27 (Suppl. 2): S56 (Abstract 308).Google Scholar
  124. Pizzo, P. A., Hathorn, J. W., and Hiemenz, J., 1986, A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropaenia, N. Engl. J. Med. 315: 552–558.PubMedGoogle Scholar
  125. Pojda, Z., and Struzyna, J., 1994, Treatment of non-healing ulcers with rhGM-CSF and skin grafts, Lancet 343: 1100.PubMedGoogle Scholar
  126. Powles, R., Smith, C., Milan, S., Treleaven, J., Millar, J., McElwain, T., Gordon-Smith, E., Milliken, S., and Tiley, C., 1990, Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukaemia: Double-blind placebo controlled trial, Lancet 336: 1417–1420.PubMedGoogle Scholar
  127. Rusthoven, J., Sheperd, F. A., and Goss, P. E., 1992, Phase 1 trial of GM-CSF with high dose carboplatin and etoposide for the treatment of small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group (letter), J. Natl. Cancer Inst. 84: 59–60.PubMedGoogle Scholar
  128. Rabinowe, S., Freedman, A., and Demetri, G., 1990, Randomized double blind trial of rhGM-CSF in patients with B-cell non-Hodgkin’s lymphoma (B-NHL) undergoing high dose chemoradiotherapy and monoclonal antibody purged autologous bone marrow transplantation (ABMT), Blood 76 (Suppl. 1): 161.Google Scholar
  129. Reiffers, J., Bernard, P., and David, B., 1986, Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia, Exp. Hematol. 14: 312–315.PubMedGoogle Scholar
  130. Richman, C. M., Winer, R. S., and Yankee, R. A., 1976, Increase in circulating stem cells following chemotherapy in man, Blood 47: 1031–1039.PubMedGoogle Scholar
  131. Russell, N. H., Hunter, A., Rogers, S., Hanley, J., and Anderson, D., 1993, Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation, Lancet 341: 1482.PubMedGoogle Scholar
  132. Schuster, N. U., Larson, R. A., Thompson, J. A., Coiffier, B., Bennett, J. M., and Israel, R. J., 1990, Granulocyte—macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS); results of a multi-centre randomised trial, Blood 76 (Suppl.): 1263a.Google Scholar
  133. Schwartzberg, L., West, W., Birch, R., and Blanco, R., 1992, G-CSF improves peripheral blood stem cells (PBSC) mobilization and hematologic reconstitution after high-dose chemotherapy. Int. J. Cell Cloning 10 (Suppl. 1): 193.Google Scholar
  134. Schwinger, W., Mache, C., Urban, C., Beaufort, F., and Toglhofer, W., 1993, Single dose of filgrastim (rhG-CSF) increases the number of hematopoietic progenitors in the peripheral blood of adult volunteers, Bone Marrow Transplant. 11: 489–492.PubMedGoogle Scholar
  135. Shea, T. C., Mason, J. R., Newton, B., Storniolo, A. M., Taetle, R., and Green, M. R., 1990, High-dose carboplatin (CBDCA) with recombinant human granulocyte—macrophage colony stimulating factor (rHu-GM-CSF): A phase 1 study, Proc. Am. Soc. Clin. Oncol. 9: 286 (Abstract 1109).Google Scholar
  136. Sheridan, W. P., Morstyn, G., and Wolf, M., 1989, Granulocyte colony-stimulating factor and neutrophil recovery after high dose chemotherapy and autologous bone marrow transplantation, Lancet 2: 890–895.Google Scholar
  137. Sheridan, W. P., Begley, C. G., and Juttner, C. A., 1992, Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy, Lancet 339: 640–644.PubMedGoogle Scholar
  138. Singer, J. W., Nemunaitis, J., and Bianco, J. C., 1990a, RhGM-CSF following allogeneic bone marrow transplantation from unrelated marrow donors: A phase II study, Blood 76 (Suppl. 1): 566.Google Scholar
  139. Singer, J. W., Nemunaitis, J., and Buckner, C. D., 19906, Phase I/II trial of rhGM-CSF after allogeneic bone marrow transplantation (BMT), J. Cell Biochem. (Suppl.) 14a:333.Google Scholar
  140. Skipper, H. E., 1967, Criteria associated with destruction of leukaemia and solid tumour cells in animals, Cancer Res. 27 (1): 2636–2645.PubMedGoogle Scholar
  141. Socinski, M. A., Cannistra, S. A., Elias, A., Antman, K. H., Schnipper, L., and Griffin, J. D., 1988, Granulocyte—macrophage colony-stimulating factor expands the circulating hemopoietic progenitor cell compartment in man, Lancet 1: 1194–1198.PubMedGoogle Scholar
  142. Spitzer, G., Mathews, M., Dunphy, F., Bowers, C., Petruska, R, Velasquez, W., Broun, G., Kronmueller, N., Niemeyer, R., McIntyre, W., and Adkins, D.,1994ó, Are growth factor (GF) combinations superior to G-CSF alone for mobilization of peripheral blood stem cells (PBSC): A randomized study comparing G-CSF with GM-CSF for PBSC mobilization, Blood 84(Suppl. 1 ): 415.Google Scholar
  143. Steward, W. R, Scarffe, J. H., Dirix, L. Y., Chang, J., Radford, J. A., Bonnem, E., and Crowther, D., 1990, Granulocyte—macrophage colony-stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer, Br. J. Cancer 61: 749–954.PubMedGoogle Scholar
  144. Stiff, P. J., Koester, A. R., and Weidner, M. K., 1987, Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled rate freezing, Blood 70: 974–978.PubMedGoogle Scholar
  145. Stoppa, A. M., Blaise, D., and Viens, R, 1984, Phase I study of in vivo lenograstim (rHuG-CSF) for stem cell collection demonstrates improved neutrophil recovery after autologous bone marrow transplantation, Bone Marrow Transplant. 13: 541–547.Google Scholar
  146. Sutherland, H. J., Eaves, C. J., Lansdorp, R. M., Phillips, G. L., and Hogge, D. E., 1994, Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants, Blood 83: 3808–3814.PubMedGoogle Scholar
  147. Taylor, K. M., Jagannath, S., and Spitzer, G., 1989, Recombinant human granulocyte colony-stimulating factor hastens granulocytic recovery after high-dose chemotherapy and autologous bone marrow transplantation, J. Clin. Oncol. 7 (12): 1791–1799.PubMedGoogle Scholar
  148. Tejero, C., Testa, N. G., and Lord, B. I., 1984, The cellular specificity of haemopoietic stem cell proliferation regulators, Leuk. Res. 8: 1073–1083.Google Scholar
  149. Teshima, H., Ishikawa, J., and Kitawama, H., 1989, Clinical effects of recombinant human granulocyte colony-stimulating factor in leukemia patients: A phase I/II study, Exp. Hematol. 17: 853–858.PubMedGoogle Scholar
  150. Thompson, J. A., Lee, D. J., Kidd, R, Rubin, E., Kaufmann, J., Bonnem, E. M., and Fefer, A., 1989, Subcutaneous granulocyte—macrophage colony-stimulating factor in patients with myelodysplastic syndrome: Toxicity, pharmacokinetics and hematological effects, J. Clin. Oncol. 7: 629–637.PubMedGoogle Scholar
  151. To, L. B., Dyson, P. G., and Branford, A., 1987, Peripheral blood stem cells collected in very early remission produce rapid and sustained autologous hematopoietic reconstitution in acute non-lymphoblastic leukaemia, Bone Marrow Transplant. 2: 103–108.PubMedGoogle Scholar
  152. Trillet-Lenoir, V., Green, J., and Manegold, C., 1993, Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy, Eur J. Cancer 29A: 319–324.Google Scholar
  153. Usuki, K., Iki, S., Endo, M., Ito, K., Kitasume, K., Watanabe, M., and Urabe, A., 1994, Granulocyte colony-stimulating factor in acute myeloid leukemia, Blood 84 (Suppl. 1): 86.Google Scholar
  154. Vadhan-Raj, S., Keating, M., LeMaistre, A., Hittelman, W. N., McCredie, K., Trujillo, J. M., Broxmeyer, H. E., Henney, C., and Gutterman, J. U., 1987, effects of recombinant human granulocyte–macrophage colony-stimulating factor in patients with myelodysplastic syndromes, N. Engl. J. Med. 317: 1545–1552.Google Scholar
  155. Vadhan-Raj, S., Broxmeyer, H. E., and Spitzer, G., 1989, Stimulation of non-clonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte–macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome, Blood 74: 1491.PubMedGoogle Scholar
  156. Vadhan-Raj, S., Broxmeyer, H. E., Hittleman, W. N., Papadopoulos, N. E., Chawla, S. P., Fenoglio, C., and Cooper, S., 1992, Abrogating chemotherapy induced myelosuppression by recombinant granulocyte–macrophage colony-stimulating factor in patients with sarcoma: Protection at the progenitor cell level, J. Clin. Oncol. 10: 1266–1277.PubMedGoogle Scholar
  157. Venturini, M., Sertoli, M. R., and Ardizzoni, A., 1992, Prospective randomized trial of accelerated FEC chemo- therapy with or without GM-CSF in advanced breast carcinoma, Proc. Am. Soc. Clin. Oncol. 11: 36.Google Scholar
  158. Villeval, J.-L., Duhrsen, U., Morstyn, G., and Metcalf, D., 1990, Effect of recombinant human granulocyte–macrophage colony-stimulating factor on progenitor cells in patients with advanced malignancies, Br. J. Haematol. 74: 36–44.PubMedGoogle Scholar
  159. Wdzieczak-Bakala, J., Guigon, M., Lenfant, M., and Frindel, E., 1983, Further purification of a CFU-S inhibitor: In vivo effects after cytosine arabinoside treatment, Biomed. Pharmacother. 37: 467–471.PubMedGoogle Scholar
  160. Wdzieczak-Bakala, J., Fache, M. P., Lenfant, M., Frindel, E., and Sainteny, F., 1990, AcDSKP, an inhibitor of CFUS proliferation, is synthesized in mice under steady state conditions and secreted by bone marrow in long term culture, Leukemia 4: 235–237.PubMedGoogle Scholar
  161. Weaver, A., Wrigley, E., Jenkins, B., Matcham, J., Ewen, C., Dexter, T. M., Testa, N. G., and Crowther, D., 1995, Effects of filgrastim (G-CSF) alone or in combination with chemotherapy on the mobilisation of peripheral blood progenitor cells: Early results from a pilot study of high dose chemotherapy in ovarian cancer, in Proceedings of International Conference on Recent Advances in Hematopoietic Stem Cell Transplantation—Clinical Progress, New Technologies and Gene Therapy, San Diego, Abstract 16, p. 379.Google Scholar
  162. Wiley, J., Cebon, J., Woodruff, R., Jamieson, G., Snook, M., McKendrick, J., Szer, J., Dennington, P., Sheridan, W., Begley, G., van der Weyden, M., and Fox, R., 1991, Granulocyte–macrophage colony-stimulating factor followed by chemotherapy in the treatment of poor prognosis acute myeloid leukemia, Blood 78 (suppl): 42a.Google Scholar
  163. Yoshida, Y., Hirashima, K., Asano, S., and Takaku, F., 1991, A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes, Br. J. Haematol. 78: 378–384.PubMedGoogle Scholar
  164. Zeller, W., Cassens, U., Stockschlader, M., Kruger, W., Kabisch, H., Kuhnl, P., Hossfeld, D. K., and Zander, A. R., 1994, Higher dose of G-CSF increases yield of mobilized CD34+ cells, Blood 84 (Suppl. 1): 413.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Andrew Weaver
    • 1
  • Nydia G. Testa
    • 1
  1. 1.Cancer Research Campaign Departments of Experimental Haematology and Medical OncologyChristie Hospital NHS TrustManchesterUK

Personalised recommendations